 Atea Pharmaceuticals Inc NASDAQ: AVIR has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license agreement with Roche Holding AG OTC: RHHBY of 50 million. Under the license agreement, Roche and Atea are jointly developing AT-527 for the treatment of COVID-19. 